Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing

Clinical Pharmacology and Therapeutics

Volumn 108, Issue 2, 2020, Pages 253-263

  Garcia Cremades, Maria ^a   Solans, Belen P ^a   Hughes, Emma ^a   Ernest, Jacqueline P ^a   Wallender, Erika ^a   Aweeka, Francesca ^a   Luetkemeyer, Anne F ^b   Savic, Radojka M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; HYDROXYCHLOROQUINE; ANTIVIRUS AGENT;

ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CORONAVIRUS DISEASE 2019; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG REPOSITIONING; DRUG SAFETY; EC50; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KINETICS; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; OPTIMAL DRUG DOSE; PHARMACODYNAMICS; PHARMACOKINETIC PARAMETERS; PREDICTION; PRIORITY JOURNAL; QT PROLONGATION; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; VIRAL CLEARANCE; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; VOLUME OF DISTRIBUTION; BETACORONAVIRUS; BIOLOGICAL MODEL; CORONAVIRUS INFECTION; DRUG EFFECT; PHYSIOLOGY; REPRODUCIBILITY; SARS CORONAVIRUS; TRANSLATIONAL RESEARCH; VIROLOGY;

ANTIVIRAL AGENTS; BETACORONAVIRUS; CORONAVIRUS INFECTIONS; DRUG REPOSITIONING; HUMANS; HYDROXYCHLOROQUINE; MODELS, BIOLOGICAL; REPRODUCIBILITY OF RESULTS; SARS VIRUS; TRANSLATIONAL MEDICAL RESEARCH; VIRAL LOAD; VIRUS REPLICATION;

EID: 85083419365     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.1856     Document Type: Article

References (50)

1. World Health Organization. (2020). Coronavirus disease (COVID-19) outbreak situation (Geneva, Switzerland,2020).
2. Biot, C. et al. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. J. Med. Chem. 49, 2845–2849 (2006).
3. Yao, X. et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis. (2020). https://doi.org/10.1093/cid/ciaa237
4. Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30, 269–271 (2020).
5. Schrezenmeier, E. & Dorner, T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat. Rev. Rheumatol. 16, 155–166 (2020).
6. Gautret, P. et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents 105949, (2020). https://doi.org/10.1016/j.ijantimicag.2020.105949
7. Jun, C. et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J. Zhejiang Univ. (Med Sci) 49, (2020). https://doi.org/10.3785/j.issn.1008-9292.2020.03.03
8. Centers for Disease Control and Prevention.Information for clinicians on therapeutic options for COVID-19 patients (2020).
9. Liu, J. et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 6, 16 (2020).
10. Touret, F. et al. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. bioRxiv. https://doi.org/10.1101/2020.04.03.023846
11. Rohatgi, A.W. WebPlotDigitizer (2019).
12. Kaye, M. SARS-associated coronavirus replication in cell lines. Emerg. Infect. Dis. 12, 128–133 (2006).
13. Mulangu, S. et al. A randomized, controlled trial of Ebola virus disease therapeutics. N. Engl. J. Med. 381, 2293–2303 (2019).
14. Gautret, P. et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study. Travel Med Infect Dis. (2020). https://doi.org/10.1016/j.tmaid.2020.101663
15. Lim, H.S. et al. Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. Antimicrob. Agents Chemother. 53, 1468–1475 (2009).
16. Uges, D.R. Plasma or serum in therapeutic drug monitoring and clinical toxicology. Pharm. Weekbl. Sci. 10, 185–188 (1988).
17. Ahn, J.E., Karlsson, M.O., Dunne, A. & Ludden, T.M. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J. Pharmacokinet. Pharmacodyn. 35, 401–421 (2008).
18. Beal, S.L. Ways to fit a PK model with some data below the quantification limit. J. Pharmacokinet. Pharmacodyn. 28, 481–504 (2001).
19. Ursing, J. et al. High-dose chloroquine for uncomplicated Plasmodium falciparum malaria is well tolerated and causes similar QT interval prolongation as standard-dose chloroquine in children. Antimicrob. Agents Chemother. 64, (2020). https://doi.org/10.1128/AAC.01846-19
20. Mzayek, F. et al. Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. PLoS Clin. Trials 2, e6 (2007).
21. Cao, B. et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N. Engl. J. Med. (2020). https://doi.org/10.1056/NEJMoa2001282
22. Balevic, S.J. et al. Pharmacokinetics of hydroxychloroquine in pregnancies with rheumatic diseases. Clin. Pharmacokinet. 58, 525–533 (2019).
23. Hydroxychloroquine. Package Insert. (Concordia Pharmaceuticals Inc., St. Michael, Barbados, 2017).
24. Chinappi, M., Via, A., Marcatili, P. & Tramontano, A. On the mechanism of chloroquine resistance in Plasmodium falciparum. PLoS One 5, e14064 (2010).
25. Collins, K.P., Jackson, K.M. & Gustafson, D.L. Hydroxychloroquine: a physiologically-based pharmacokinetic model in the context of cancer-related autophagy modulation. J. Pharmacol. Exp. Ther. 365, 447–459 (2018).
26. Daniel, W.A., Bickel, M.H. & Honegger, U.E. The contribution of lysosomal trapping in the uptake of desipramine and chloroquine by different tissues. Pharmacol. Toxicol. 77, 402–406 (1995).
27. Sarathy, J.P. et al. Prediction of drug penetration in tuberculosis lesions. ACS Infect. Dis. 2, 552–563 (2016).
28. Strydom, N. et al. Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization. PLoS Med. 16, e1002773 (2019).
29. Warhurst, D.C., Steele, J.C., Adagu, I.S., Craig, J.C. & Cullander, C. Hydroxychloroquine is much less active than chloroquine against chloroquine-resistant Plasmodium falciparum, in agreement with its physicochemical properties. J. Antimicrob. Chemother. 52, 188–193 (2003).
30. de Olano, J., Howland, M.A., Su, M.K., Hoffman, R.S. & Biary, R. Toxicokinetics of hydroxychloroquine following a massive overdose. Am. J. Emerg. Med. 37, e5–e8 (2019).
31. O'Laughlin, J.P., Mehta, P.H. & Wong, B.C. Life threatening severe QTc prolongation in patient with systemic lupus erythematosus due to hydroxychloroquine. Case Rep. Cardiol. 2016, 4626279 (2016).
32. Chen, C.Y., Wang, F.L. & Lin, C.C. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clin. Toxicol. (Phila). 44, 173–175 (2006).
33. Negoescu, A., Thornback, A., Wong, E. & Ostor, A.J. Long QT and hydroxychloroquine; a poorly recognised problem in rheumatology patients. In ACR/ARHP Annual Meeting (2013). Abstract number 2045.
34. Kazama, I., Maruyama, Y., Murata, Y. & Sano, M. Voltage-dependent biphasic effects of chloroquine on delayed rectifier K(+)-channel currents in murine thymocytes. J. Physiol. Sci. 62, 267–274 (2012).
35. Giudicessi, J.R., Noseworthy, P.A., Friedman, P.A. & Ackerman, M.J. Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19). Mayo Clin. Proc. (2020). https://doi.org/10.1016/j.mayocp.2020.03.024
36. Rodriguez-Menchaca, A.A. et al. The molecular basis of chloroquine block of the inward rectifier Kir2.1 channel. Proc. Natl. Acad. Sci. USA 105, 1364–1368 (2008).
37. Newton, D.W. & Kluza, R.B. pKa values of medicinal compounds in pharmacy practice. Drug Intell. Clin. Phar. 12, 546–554 (1978).
38. White, N.J. Cardiotoxicity of antimalarial drugs. Lancet Infect. Dis. 7, 549–558 (2007).
39. Munster, T. et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum. 46, 1460–1469 (2002).
40. Rangwala, R. et al. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy 10, 1369–1379 (2014).
41. Tisdale, J.E. et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ. Cardiovasc. Qual. Outcomes 6, 479–487 (2013).
42. Melles, R.B. & Marmor, M.F. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 132, 1453–1460 (2014).
43. Chansky, P.B. & Werth, V.P. Accidental hydroxychloroquine overdose resulting in neurotoxic vestibulopathy. BMJ Case Rep. 2017, (2017). https://doi.org/10.1136/bcr-2016-218786
44. Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020).
45. Zou, L. et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N. Engl. J. Med. 382, 1177–1179 (2020).
46. Pan, Y., Zhang, D., Yang, P., Poon, L.L.M. & Wang, Q. Viral load of SARS-CoV-2 in clinical samples. Lancet Infect. Dis. 20, 411–412 (2020).
47. Wolfel, R. et al. Virological assessment of hospitalized patients with COVID-2019. Nature (2020). https://doi.org/10.1038/s41586-020-2196-x
48. Wang, W. et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA (2020). https://doi.org/10.1001/jama.2020.3786
49. Zou, X., Chen, K., Zou, J., Han, P., Hao, J. & Han, Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front. Med. (2020). https://doi.org/10.1007/s11684-020-0754-0
50. Xu, H. et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int. J. Oral Sci. 12, 8 (2020).